STAT+: FDA spells out 2027 AI guidance plans
Reported by STAT News · all stories from statnews.com
Editorial digest
The Food and Drug Administration has outlined its intentions for providing guidance regarding artificial intelligence by the year 2027. This information offers insight into upcoming regulatory developments for health technology.
Digests are written in our own words from the publisher's headline — we never reproduce article text. Read the original for the full reporting.
Read the full story at STAT News →More like this
Other stories our editors tagged with the same themes.
- Trusted health newsroom10/22/2026
STAT+: FDA finalizes its guidance on apps related to drugs, pharma rejoices
Federal regulators have completed formal guidelines for software applications paired with medications, drawing positive reactions from pharmaceutical manufacturers.
- Trusted health newsroom11/3/2026
STAT+: FDA, CMS look to collaborate with states on health AI
Federal regulators at the FDA and CMS plan to partner with state authorities regarding medical artificial intelligence.
- Trusted health newsroom10/30/2026
STAT+: FDA, CMS scramble to avoid regulatory logjam as more states look to test AI in clinical settings
Federal health agencies are working quickly to prevent oversight bottlenecks as states prepare clinical artificial intelligence trials.
- Trusted health newsroom10/22/2026
STAT+: Telehealth leapfrogs FDA approval with off-label GLP-1 prescriptions for addiction
Virtual clinics are providing off-label GLP-1 therapies for substance use disorders before receiving formal regulatory authorization.
- Trusted health newsroom11/5/2026
STAT+: What the midterms could mean for the future of health AI
Upcoming midterm election outcomes could reshape regulatory policies and federal oversight for medical artificial intelligence technologies.
- Trusted health newsroom10/7/2026
STAT+: Why health AI pilots in Utah may be on a collision course with the FDA
Utah's healthcare artificial intelligence trials may conflict with federal regulatory bodies.